This announcement is a separate document:
康方生物：自願公告 - 國家藥品監督管理局受理康方生物自主研發的依若奇單抗注射液（IL-12 / IL-23單克隆抗體，AK101）的新藥上市申請
AKESO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR THE EBDAROKIMAB INJECTION (IL-12/IL-23 MONOCLONAL ANTIBODY, AK101) INDEPENDENTLY-DEVELOPED BY AKESO
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.